Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your US drug review and approval news news in brief: Industry may have some relief on the horizon with President Trump and congressional leaders agreeing to a three-week continuing resolution to re-open the government, but it was a bad week for two big pharmas in Bristol-Myers Squibb Co. and Eli Lilly & Co.

For Bristol, it was another disappointment for its PD-1 inhibitor Opdivo (nivolumab). The drugmaker has withdrawn its supplemental biologics license...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet